A research team involving scientists from the German Center for Lung Research (DZL) has now gained important insights into the processes that determine whether pulmonary fibrosis progresses or resolves. The findings were published in Nature...
Researchers at the CPC-M site in Munich of the DZL have uncovered evidence that asthma may originate very early in life. Their recent study shows that children who later develop asthma already exhibit measurable differences...
Researchers have investigated how modern CFTR modulators in cystic fibrosis affect not only the lungs but also the body’s overall proteome. The study provides new insights into the systemic effects of highly effective therapies.
New hope for pulmonary fibrosis: Researchers at the Heidelberg site of the German Center for Lung Research (DZL) have developed an immunotherapy-based approach that selectively eliminates senescent fibroblasts and could promote lung regeneration. The findings...
How is artificial intelligence transforming pulmonary research? At the DZL DataLung Symposium 2026, researchers, clinicians, and data scientists gathered at Schloss Rauischholzhausen to discuss innovative AI approaches, data-driven research, and interdisciplinary collaboration.
International experts in clinical, translational, and basic science research gathered in Giessen, Germany, from May 6–8, 2026, for the eurILDreg Symposium “Re-shaping eurILDreg: structure, organisation, research goals” to discuss current developments and future strategies in...
During the 64th Annual Meeting of the German Society of Nuclear Medicine (DGN), Prof. Uwe Haberkorn was awarded the Georg von Hevesy Medal. With this distinction, the DGN recognizes outstanding scientific achievements that have made...
A recent study at the DZL partner site BREATH shows that the protein S100A8 plays a crucial role in the lung’s immune defense against bacterial pneumonia. The findings open up new perspectives for diagnostic and...
A research team, with participation from the DZL, has developed an innovative human “lung-on-a-chip” model that realistically replicates key mechanisms of ventilator-associated pneumonia (VAP).
A recent scientific statement from the American Heart Association, published in the journal Circulation, places greater emphasis on right ventricular function in both research and clinical care for pulmonary hypertension (PH).
A newly developed nanobody could significantly expand treatment options for cystic fibrosis. For the first time, researchers have succeeded in engineering a cell-permeable antibody fragment that acts directly inside cells and stabilises the CFTR channel,...
A recent study published in the Journal of Controlled Release explores innovative strategies to deliver RNA-based therapies directly to the lungs. The findings provide important impulses for the development of new treatment approaches for inflammatory...
